Incyte Corp (NAS:INCY)
$ 57.0387 -0.0113 (-0.02%) Market Cap: 12.83 Bil Enterprise Value: 8.99 Bil PE Ratio: 17.28 PB Ratio: 2.37 GF Score: 86/100

Incyte Corp at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 04:20PM GMT
Release Date Price: $79.06 (+4.84%)
Marc Alan Frahm
Cowen and Company, LLC, Research Division - VP

All right. Thanks for joining here at the Cowen Health Care Conference. Before anything else -- at Cowen Health Care Conference. Really excited to start off the company presentations today with -- fireside chat here with Incyte. We have Steven Stein, the CMO; and Christiana Stamoulis, the CFO, with us.

Questions & Answers

Marc Alan Frahm
Cowen and Company, LLC, Research Division - VP

Maybe just to start off, Christiana, if you want to talk -- a year or so ago, some investors were worried that the launch of INREBIC could kind of increase the rate of Jakafi discontinuations and really impact kind of trends on Jakafi. So maybe if you can -- now that we're about 7 months into the launch, say, discuss how INREBIC has actually changed the market, good, bad or your insight for Jakafi trends? And any impact on pricing flexibility kind of moving forward?

Christiana Stamoulis
Incyte Corporation - Executive VP & CFO

Okay, great. Is this working?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot